ESTRO35 Programme Book

ELECTRONIC POSTERS

> Normal tissue exposure in SBRT: Retrospective QA on a prospective cohort - what have we learned? S. Adebahr (Germany), J. Hinck, R. Wiehle, T. Schimek-Jasch, E. Gkika, A.L. Grosu, U. Nestle > Relationship of dosimetric findings and toxicity following SABR for lung cancer K. Johnson (UK), A. Morenc, T. Sridhar, L. Aznar-Garcia > stereotactic body radiation therapy for early stage NSCLC: clinical outcomes A. Iurato (Italy), A. Carnevale, E. Ippolito, M. Fiore, C. Greco, L.E. Trodella, A. Di Donato, S. Ramella, R.M. D’Angelillo, L. Trodella > A multicentre clinical trial using 3DCRT to reduce toxicity of palliative radiation for lung cancer R. McDermott (Ireland) > Radiotherapy for loco-regional recurrence of non-small-cell lung cancer after complete resection > BED <100Gy and ITV ≥20cc predict local relapse after stereotactic radiation therapy for lung cancer A. Suissa (France), A. Levy, F. Belkhir, N. Grellier-Adedjouma, P. Xu, F. Martinetti, C. Le Péchoux > Is there a different dose-effect relation between the tumour and involved lymph nodes in NSCLC? L. Van den Bosch (Belgium), G. Defraene, S. Peeters, C. Dooms, W. De Wever, C. Deroose, D. De Ruysscher > Is CC Chemokine Ligand 18 a biomarker for the prediction of radiation induced lung disease? E. Gkika (Germany), S. Adebahr, T. Schimek-Jasch, A. Brenner, T. Brunner, A. Prasse, G. Ziessel, A.L. Grosu, U. Nestle > Lung re-irradiation with stereotactic body radiation therapy (SBRT) P. Bonome (Italy), C. Scaringi, M. Valeriani, V. De Sanctis, G. Minniti, M.F. Osti K. Terashima (Japan), M. Inamori, A. Matsunobu, H. Hirata, K. Sakamoato, K. Okabayashi, A. Furuya, M. Hirakawa

EP-1240

EP-1241

EP-1242

EP-1243

EP-1244

EP-1245

EP-1246

EP-1247

EP-1248

POSTERS AND ELECTRONIC POSTERS | PROGRAMME AND EXHIBITION GUIDE

235